37 research outputs found

    ЭпидСмиологичСский ΠΎΠ±Π·ΠΎΡ€ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, ΠΏΠΎΡ‡ΠΊΠΈ ΠΈ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря

    Get PDF
    Background. In recent years, an increase in the incidence of multiple primary malignancies has been observed. Multiple primary malignancies are an independent occurrence and development of two or more neoplasms of different histological origin in one patient.Aim. To evaluate epidemiological, clinical and morphological aspects of primary multiple malignant neoplasms of the prostate, kidney, and bladder.Materials and methods. Data analysis of the work report of the Saratov region oncological service in 2019, presented by the Regional Clinical Oncological Dispensary, patient case histories in the archive of the medical information system was performed.We performed a comparative analysis of the literature sources and data we obtained based to the following criteria: topographic anatomical combination of tumor locations, distribution of tumor combinations depending on time of occurrence (synchronous, metachronous), dynamics of urogenital multiple primary malignancies diagnosis in 2012-2019, distribution by gender and age, combination of stages of tumor process in both tumors, distribution by combination of histological types.Results. Between 2012 and 2019, 783 cases of multiple primary tumors with lesions in the urogenital system were identified. We studied 186 cases with a combination of two malignant neoplasms in the prostate, kidney, and bladder. Tumors developed synchronously in 36 % of patients, metachronously in 64 %. Mean patient age was 75 years. Half of the cases were in the group of localized stages - 90 (48.4 %), with the most common combination of TI-TII stages observed in 46 (24.7 %) cases. Combinations of acinar adenocarcinoma of the prostate with urothelial carcinoma of the bladder (34.7 %), clear cell renal carcinoma (27.8 %), papillary urothelial carcinoma of the bladder (12.5 %) were the most common according to histological diagnosis of primary multiple tumors of the urogenital system.Conclusion. Over the recent years we can observe a steady growth of diagnosable urogenital multiple primary malignancies. Morphological verification of the tumor and revelation of the most frequent histological types allows to assume the presence of the common mechanisms of development and the influence of tumor microenvironment on the growth of both tumors in a multiple primary malignancies pair.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Π’ послСдниС Π³ΠΎΠ΄Ρ‹ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½ΠΎ ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½ΠΈΠ΅ частоты ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠŸΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнныС злокачСствСнныС новообразования - нСзависимоС Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠ΅ ΠΈ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ Ρƒ 1 больного 2 ΠΈΠ»ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΠΈΠΌΠ΅ΡŽΡ‚ Ρ€Π°Π·Π½ΠΎΠ΅ гистологичСскоС происхоТдСниС.ЦСль исслСдования - ΠΎΡ†Π΅Π½ΠΊΠ° эпидСмиологичСских ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСских аспСктов ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, ΠΏΠΎΡ‡ΠΊΠΈ ΠΈ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· Π΄Π°Π½Π½Ρ‹Ρ… Π½Π° основании ΠΎΡ‚Ρ‡Π΅Ρ‚Π° ΠΏΠΎ ΠΈΡ‚ΠΎΠ³Π°ΠΌ Ρ€Π°Π±ΠΎΡ‚Ρ‹ онкологичСской слуТбы Баратовской области Π² 2019 Π³., прСдставлСнным ΠžΠ±Π»Π°ΡΡ‚Π½Ρ‹ΠΌ клиничСским онкологичСским диспансСром, историй Π±ΠΎΠ»Π΅Π·Π½ΠΈ, находящихся Π² Π°Ρ€Ρ…ΠΈΠ²Π΅ мСдицинской ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΉ систСмы.Π’Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ ΡΡ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ· источников Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ ΠΈ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… Π½Π°ΠΌΠΈ Π΄Π°Π½Π½Ρ‹Ρ… ΠΏΠΎ ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠΌ критСриям: Ρ‚ΠΎΠΏΠΎΠ³Ρ€Π°Ρ„ΠΎ-анатомичСскоС сочСтаниС Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΉ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ, распрСдСлСниС сочСтания ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ Π² зависимости ΠΎΡ‚ Π²Ρ€Π΅ΠΌΠ΅Π½ΠΈ возникновСния (синхронноС, ΠΌΠ΅Ρ‚Π°Ρ…Ρ€ΠΎΠ½Π½ΠΎΠ΅), Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° диагностики ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΌΠΎΡ‡Π΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ систСмы Π·Π° 2012-2019 Π³Π³., распрСдСлСниС ΠΏΠΎ ΠΏΠΎΠ»Ρƒ ΠΈ возрасту, сочСтаниС стадий ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ процСсса Π² ΠΎΠ±Π΅ΠΈΡ… опухолях, распрСдСлСниС ΠΏΠΎ ΡΠΎΡ‡Π΅Ρ‚Π°Π½ΠΈΡŽ гистологичСских Ρ‚ΠΈΠΏΠΎΠ².Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π—Π° ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ 2012-2019 Π³Π³. выявлСно 783 случая ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ с ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΎΡ€Π³Π°Π½ΠΎΠ² ΠΌΠΎΡ‡Π΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ систСмы. Π˜Π·ΡƒΡ‡Π΅Π½ΠΎ 186 случаСв с сочСтаниСм 2 злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΡ… ΠΎΡ€Π³Π°Π½Π°Ρ…: ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Π΅, ΠΏΠΎΡ‡ΠΊΠ΅, ΠΌΠΎΡ‡Π΅Π²ΠΎΠΌ ΠΏΡƒΠ·Ρ‹Ρ€Π΅. ΠžΠΏΡƒΡ…ΠΎΠ»ΠΈ Ρ€Π°Π·Π²ΠΈΠ²Π°Π»ΠΈΡΡŒ синхронно Ρƒ 36 % ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², ΠΌΠ΅Ρ‚Π°Ρ…Ρ€ΠΎΠ½Π½ΠΎ - Ρƒ 64 %. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ возраст ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² составил 75 Π»Π΅Ρ‚. Половина случаСв ΠΎΡ‚Π½ΠΎΡΠΈΠ»Π°ΡΡŒ ΠΊ Π³Ρ€ΡƒΠΏΠΏΠ΅ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹Ρ… стадий - 90 (48,4 %), ΠΏΡ€ΠΈΡ‡Π΅ΠΌ самым распространСнным Π±Ρ‹Π»ΠΎ сочСтаниС стадии TI-TII - 46 (24,7 %). ΠŸΡ€ΠΈ гистологичСской диагностикС ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΌΠΎΡ‡Π΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ систСмы ΠΏΡ€Π΅ΠΎΠ±Π»Π°Π΄Π°Π»ΠΈ сочСтания Π°Ρ†ΠΈΠ½Π°Ρ€Π½ΠΎΠΉ Π°Π΄Π΅Π½ΠΎΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ с ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠΎΠΉ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря (34,7 %), свСтлоклСточным Ρ€Π°ΠΊΠΎΠΌ ΠΏΠΎΡ‡ΠΊΠΈ (27,8 %), папиллярной ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠΎΠΉ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря (12,5 %).Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π—Π° послСдниС Π³ΠΎΠ΄Ρ‹ Π½Π°Π±Π»ΡŽΠ΄Π°Π΅Ρ‚ΡΡ постоянный рост диагностируСмых ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных Π·Π»ΠΎΠΊΠ°-чСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΌΠΎΡ‡Π΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ систСмы. ΠœΠΎΡ€Ρ„ΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠ°Ρ вСрификация ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΈ выявлСниС Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ часто Π²ΡΡ‚Ρ€Π΅Ρ‡Π°ΡŽΡ‰ΠΈΡ…ΡΡ гистологичСских Ρ‚ΠΈΠΏΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ ΠΏΡ€Π΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚ΡŒ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ ΠΎΠ±Ρ‰ΠΈΡ… ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΠΎΠ² развития ΠΈ влияния ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ микроокруТСния Π½Π° рост ΠΎΠ±Π΅ΠΈΡ… ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΈΠ· ΠΏΠ°Ρ€Ρ‹ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ-мноТСствСнных злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ

    Photothermal and photodynamic therapy of tumors with plasmonic nanoparticles: challenges and prospects

    Get PDF
    Cancer remains one of the leading causes of death in the world. For a number of neo-plasms, the efficiency of conventional chemo-and radiation therapies is insufficient because of drug resistance and marked toxicity. Plasmonic photothermal therapy (PPT) using local hyperthermia induced by gold nanoparticles (AuNPs) has recently been extensively explored in tumor treatment. However, despite attractive promises, the current PPT status is limited by laboratory experiments, academic papers, and only a few preclinical studies. Unfortunately, most nanoformulations still share a similar fate: great laboratory promises and fair preclinical trials. This review discusses the current challenges and prospects of plasmonic nanomedicine based on PPT and photodynamic therapy (PDT). We start with consideration of the fundamental principles underlying plasmonic properties of AuNPs to tune their plasmon resonance for the desired NIR-I, NIR-2, and SWIR optical windows. The basic principles for simulation of optical cross-sections and plasmonic heating under CW and pulsed irradiation are discussed. Then, we consider the state-of-the-art methods for wet chemical synthesis of the most popular PPPT AuNPs such as silica/gold nanoshells, Au nanostars, nanorods, and nanocages. The photothermal efficiencies of these nanoparticles are compared, and their applications to current nanomedicine are shortly discussed. In a separate section, we discuss the fabrication of gold and other nanoparticles by the pulsed laser ablation in liquid method. The second part of the review is devoted to our recent experimental results on laser-activated interaction of AuNPs with tumor and healthy tissues and current achievements of other research groups in this application area. The unresolved issues of PPT are the significant accumulation of AuNPs in the organs of the mononuclear phagocyte system, causing potential toxic effects of nanoparticles, and the possibility of tumor recurrence due to the presence of survived tumor cells. The prospective ways of solving these problems are discussed, including developing combined antitumor therapy based on combined PPT and PDT. In the conclusion section, we summarize the most urgent needs of current PPT-based nanomedicine

    The assessment of effectiveness of plasmonic resonance photothermal therapy in tumor-bearing rats after multiple intravenous administration of gold nanorods

    Get PDF
    To assess the effectiveness of plasmonic photothermal therapy (PPT) multiple intravenous strategy of gold nanorods (GNRs) administration was used before laser exposure. The model of alveolar liver cancer PC-1 was used in male outbred albino rats, which were intravenously administrated by single and multiple injections of GNRs and then were treated by PPT. The gold dosage was 400 ΞΌg (single injection group), 800 ΞΌg (double injection group), 1200 ΞΌg (triple injection group), and absorption maximum of gold nanorods suspension was at the wavelength of 808 nm. 24 hours after last injection the tumors were irradiated by the 808-nm diode laser during 15 min at power density 2.3 W/cm2. Temperature control of the tumor heating was provided by IR imager. 24 hours after the PPT the half of animals from each group was withdrawn from the experiments and the sampling tumor tissue for morphological study was performed. In survived animals the growth of tumors was evaluated during 21 days after the PPT. The antitumor effects of PPT after triple intravenous injection were comparable with those obtained at direct intratumoral administration of similar total dose of GNRs. The effectiveness of PPT depended on gold accumulation in tumor, probably, due to sufficient vascularizTation of tumor tissue

    The morphological changes in transplanted tumors of rats at plasmonic photothermal therapy

    Get PDF
    The aim of work was to study the morphological changes in transplanted liver tumors of rats after plasmonic photothermal therapy (PPTT). The gold nanorods functionalized with thiolated polyethylene glycol were injected intravenously to rats with transplanted liver cancer PC-1. A day after injection the tumors were irradiated by the infrared 808-nm diode laser. The withdrawal of the animals from the experiment and sampling of tumor tissue for morphological study were performed 24 hours after the laser exposure. The standard histological and immunohistochemical staining with antibodies to proliferation marker Ki-67 and apoptosis marker BAX were used for morphological study of transplanted tumors. The plasmonic photothermal therapy had pronounced damaging effect in rats with transplanted liver tumors expressed in degenerative and necrotic changes in the tumor cells. The decrease of proliferation marker Ki-67 and increase of expression of apoptosis marker BAX were observed in tumor cells after PPTT

    The effects of prolonged oral administration of gold nanoparticles on the morphology of hematopoietic and lymphoid organs

    Get PDF
    Currently, the usage of gold nanoparticles as photosensitizers and immunomodulators for plasmonic photothermal therapy has attracted a great attention of researches and end-users. In our work, the influence of prolonged peroral administration of gold nanoparticles (GNPs) with different sizes on the morphological changes of hematopoietic and lymphoid organs was investigated. The 24 white outbred male rats weighing 180-220 g were randomly divided into groups and administered orally for 30 days the suspension of gold nanospheres with diameters of 2, 15 and 50 nm at a dosage of 190 ΞΌg/kg of animal body weight. To prevent GNPs aggregation in a tissue and enhance biocompatibility, they were functionalized with thiolated polyethylene glycol. The withdrawal of the animals from the experiment and sampling of spleen, lymph nodes and bone marrow tissues for morphological study were performed a day after the last administration. In the spleen the boundary between the red and white pulp was not clearly differ in all experimental groups, lymphoid follicles were significantly increased in size, containing bright germinative centers represented by large blast cells. The stimulation of lymphocyte and myelocytic series of hematopoiesis was recorded at morphological study of the bone marrow. The number of immunoblasts and large lymphocytes was increased in all structural zones of lymph nodes. The more pronounced changes were found in the group with administration of 15 nm nanoparticles. Thus, the morphological changes of cellular components of hematopoietic organs have size-dependent character and indicate the activation of the migration, proliferation and differentiation of immune cells after prolonged oral administration of GNPs

    The inflammation markers in serum of tumor-bearing rats after plasmonic photothermal therapy

    Get PDF
    We report on plasmonic photothermal therapy of rats with inoculated cholangiocarcinoma through the intratumoral injection of PEG-coated gold nanorods followed by CW laser light irradiation. The length and diameter of gold nanorods were 41Β±8 nm and 10Β±2 nm, respectively; the particle mass-volume concentration was 400 ΞΌg/mL, which corresponds to the optical density of 20 at the wavelength 808 nm. The tumor-bearing rats were randomly divided into three groups: (1) without any treatment (control); (2) with only laser irradiation of tumor; (3) with intratumoral administration of gold nanorods and laser irradiation of tumors. An hour before laser irradiation, the animals were injected intratumorally with gold nanorod solutions in the amount of 30% of the tumor volume. The infrared 808-nm laser with power density of 2.3 W/cm2 was used for plasmonic photothermal therapy (PTT). The withdraw of animals from the experiment was performed 24 h after laser exposure. The content of lipid peroxidation products and molecular markers of inflammation (TNF-Ξ±, IGF-1, VEGF-C) was determined by ELISA test in serum of rats. The standard histological techniques with hematoxylin and eosin staining were used for morphological examination of tumor tissues. It was revealed that the significant necrotic changes were noted in tumor tissue after plasmonic photothermal therapy, which were accompanied by formation of inflammatory reaction with release of proinflammatory cytokines and lipid peroxidation products into the bloodstream

    Liposomes loaded with hydrophilic magnetite nanoparticles: Preparation and application as contrast agents for magnetic resonance imaging

    Get PDF
    Β© 2015 Elsevier B.V.. Magnetic fluid-loaded liposomes (MFLs) were fabricated using magnetite nanoparticles (MNPs) and natural phospholipids via the thin film hydration method followed by extrusion. The size distribution and composition of MFLs were studied using dynamic light scattering and spectrophotometry. The effective ranges of magnetite concentration in MNPs hydrosol and MFLs for contrasting at both T2 and T1 relaxation were determined. On T2 weighted images, the MFLs effectively increased the contrast if compared with MNPs hydrosol, while on T1 weighted images, MNPs hydrosol contrasting was more efficient than that of MFLs. In vivo magnetic resonance imaging (MRI) contrasting properties of MFLs and their effects on tumor and normal tissues morphology, were investigated in rats with transplanted renal cell carcinoma upon intratumoral administration of MFLs. No significant morphological changes in rat internal organs upon intratumoral injection of MFLs were detected, suggesting that the liposomes are relatively safe and can be used as the potential contrasting agents for MRI

    ΠŸΠΠ’ΠžΠœΠžΠ Π€ΠžΠ— РАКА ΠŸΠ Π•Π”Π‘Π’ΠΠ’Π•Π›Π¬ΠΠžΠ™ Π–Π•Π›Π•Π—Π« ПРИ Π›Π•Π§Π•ΠΠ˜Π˜ Π’Π«Π‘ΠžΠšΠžΠ˜ΠΠ’Π•ΠΠ‘Π˜Π’ΠΠ«Πœ Π‘Π€ΠžΠšΠ£Π‘Π˜Π ΠžΠ’ΠΠΠΠ«Πœ Π£Π›Π¬Π’Π ΠΠ—Π’Π£ΠšΠžΠœ (HIFU)

    Get PDF
    The purpose of the study was to evaluate the efficiency of prostate cancer (PC) treatment using high-intensity focused ultrasound (HIFU) on the basis of morphometric and immunohistochemical (IHC) analyses of postoperative prostate biopsy specimens. The study subjects were 40 patients with localized and locally advanced PC. The postoperative morphological analysis was made on the basis of standard hematoxylineosin staining and morphometric and IHC studies using the following antibodies: PCNA, Bcl-2, AMACR, Π•-cadherin, and ANDR (Dako). Pre- and post-HIFU therapy histological examination of the routinely hematoxylin-eosin-stained specimens showed that the therapeutic pathomorphism of the tumor corresponded to grades III and IV. It was established that the IHC study should be used as an additional crite-rion for the efficiency of PC therapy after HIFU ablation. In spite of positive clinical, laboratory, instrumental, and objective changes, the patients with high AMACR and Bcl-2 levels and decreased Π•-cadherin expression may be considered as a group at risk for prolonged malignant growth or recurrent PC.ЦСль исслСдования – ΠΎΡ†Π΅Π½ΠΊΠ° эффСктивности лСчСния Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ (Π ΠŸΠ–) с использованиСм высокоинтСнсивного сфокусированного ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠ° (HIFU) Π½Π° основании морфомСтричСского ΠΈ иммуногистохимичСского (Π˜Π“Π₯) Π°Π½Π°Π»ΠΈΠ·Π° послСопСрационных Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚ΠΎΠ² ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹. ΠžΠ±ΡŠΠ΅ΠΊΡ‚ΠΎΠΌ исслСдования явились 40 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹ΠΌ ΠΈ мСстно-распространСнным Π ΠŸΠ–. ΠœΠΎΡ€Ρ„ΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· послС лСчСния ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π° основании стандартной окраски срСзов гСматоксилин-эозином, морфомСтричСского ΠΈ Π˜Π“Π₯-исслСдования с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΡ… Π°Π½Ρ‚ΠΈΡ‚Π΅Π»: PCNA, Bcl-2, AMACR, Π•-ΠΊΠ°Π΄Π³Π΅Ρ€ΠΈΠ½, ANDR (Dako). ΠŸΡ€ΠΈ гистологичСском ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠΈ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π° Π΄ΠΎ ΠΈ послС HIFU-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ ΠΏΡ€ΠΈ стандартной окраскС гСматоксилин-эозином Π»Π΅Ρ‡Π΅Π±Π½Ρ‹ΠΉ ΠΏΠ°Ρ‚ΠΎΠΌΠΎΡ€Ρ„ΠΎΠ· ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ соотвСтствовал III ΠΈ IV стСпСням. Π‘Ρ‹Π»ΠΎ выявлСно, Ρ‡Ρ‚ΠΎ Π²Β  качСствС Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ критСрия эффСктивности лСчСния Π ΠŸΠ– послС HIFU Π°Π±Π»Π°Ρ†ΠΈΠΈ Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π˜Π“Π₯-исслСдования. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ с высоким ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ AMACR, Bcl-2 ΠΈ сниТСнной экспрСссиСй Π•-ΠΊΠ°Π΄Π³Π΅Ρ€ΠΈΠ½Π°, нСсмотря Π½Π° ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½ΡƒΡŽ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ…, ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΈ ΠΎΠ±ΡŠΠ΅ΠΊΡ‚ΠΈΠ²Π½Ρ‹Ρ… ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ, ΠΌΠΎΠ³ΡƒΡ‚ Ρ€Π°ΡΡΠΌΠ°Ρ‚Ρ€ΠΈΠ²Π°Ρ‚ΡŒΡΡ ΠΊΠ°ΠΊ Π³Ρ€ΡƒΠΏΠΏΠ° риска ΠΏΡ€ΠΎΠ΄ΠΎΠ»ΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ злокачСствСнного роста Π»ΠΈΠ±ΠΎ развития Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²Π° Π ΠŸΠ–

    ВканСвая экспрСссия Π°ΡƒΡ‚ΠΎΡ„Π°Π³ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΌΠ°Ρ€ΠΊΠ΅Ρ€Π° LC3B ΠΊΠ°ΠΊ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½Ρ‹ΠΉ Π±ΠΈΠΎΠΌΠ°Ρ€ΠΊΠ΅Ρ€ Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²Π° Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ послС лСчСния высокоинтСнсивным сфокусированным ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠΌ (ΠΏΠΈΠ»ΠΎΡ‚Π½ΠΎΠ΅ исслСдованиС)

    Get PDF
    Background. The role of autophagy markers in prostate tumor recurrence has not been sufficiently investigated. We hypothesized that autophagy activation may be one mechanism by which prostate cancer cells survive exposure to high-intensity focused ultrasound (HIFU).Aim. To compare tissue expression of autophagic LC3B marker in prostate biopsies before and after treatment of localized prostate cancer by HIFU ablation.Materials and methods. 45 patients with localized morphologically confirmed prostate cancer were examined: group 1 – 25 patients of 65.6 Β± 8.4 years without signs of recurrence or progression of the disease; group 2 – 20 patients of 67.5 Β± 7.9 years with tumor recurrence proven during morphological examination. Immunohistochemical examination was performed by streptavidin-biotin method. In all cases, Anti-LC3B antibody ab48394 was used. The reaction results were quantified using the Histochemical score (Hs) system.Results. Prior to treatment, all patients of group 1 showed moderate cytoplasmic expression (Hs = 111 [111; 115]) of antibodies against LC3B in prostate adenocarcinoma cells, 5 % of patients – weak cytoplasmic expression in muscle connective stromal cells (Hs = 47 [43; 50]), 10 % of patients – weak positive LC3B reaction in the vessel wall (Hs = 28 [20; 35]). After treatment, the expression of LC3B in adenocarcinoma cells became negative, in the cytoplasm of muscle connective stromal cells weak (Hs = 75 [67.5; 80.0]), in the endothelium of the vascular wall even weaker (Hs = 55 [45.5; 60.0]) (p <0.001). Prior to treatment in group 2, LC3B expression in tumor tissue was moderate in 89 % of patients (Hs = 151.5 [137.5; 160.0]), weak in muscle connective stromal cells in 12 % of patients (Hs = 44 [35; 51.5]), and weak in the vascular wall in 5 % of patients (Hs = 30 [25; 35]). After treatment, LC3B expression in adenocarcinoma cells became pronounced (Hs = 260 [250; 285]), in muscle connective stromal cells – moderate (Hs = 118 [100; 130]), in the vascular wall – weak (Hs = 45 [30; 55]) (p <0.001). There was a significant correlation between tumor recurrence and LC3B overexpression (r = 0.51; p <0.001).Conclusion. The development of prostate cancer recurrence is associated with increased expression of autophagic LC3B protein. Increased LC3B expression, which is interpreted as evidence of autophagy activation and correlates with the risk of disease progression, is used by the tumor as an oncogenic advantage.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Роль ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² Π°ΡƒΡ‚ΠΎΡ„Π°Π³ΠΈΠΈ ΠΏΡ€ΠΈ Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²Π΅ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ нСдостаточно исслСдована. ΠœΡ‹ ΠΏΡ€Π΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΠ»ΠΈ, Ρ‡Ρ‚ΠΎ активация Π°ΡƒΡ‚ΠΎΡ„Π°Π³ΠΈΠΈ ΠΌΠΎΠΆΠ΅Ρ‚ ΡΠ²Π»ΡΡ‚ΡŒΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΠΎΠ², с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠ³ΠΎ ΠΊΠ»Π΅Ρ‚ΠΊΠΈ Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ Π²Ρ‹ΠΆΠΈΠ²Π°ΡŽΡ‚ послС воздСйствия высокоинтСнсивным сфокусированным ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠΌ (HIFU).ЦСль исслСдования – ΡΡ€Π°Π²Π½ΠΈΡ‚ΡŒ Ρ‚ΠΊΠ°Π½Π΅Π²ΡƒΡŽ ΡΠΊΡΠΏΡ€Π΅ΡΡΠΈΡŽ Π°ΡƒΡ‚ΠΎΡ„Π°Π³ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΌΠ°Ρ€ΠΊΠ΅Ρ€Π° LC3B Π² Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚Π°Ρ… ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ Π΄ΠΎ ΠΈ послС лСчСния Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ HIFU-Π°Π±Π»Π°Ρ†ΠΈΠΈ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠžΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ‹ 45 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€ΠΆΠ΄Π΅Π½Π½Ρ‹ΠΌ морфологичСски: 1-я Π³Ρ€ΡƒΠΏΠΏΠ° – 25 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (срСдний возраст 65,6 Β± 8,4 Π³ΠΎΠ΄Π°) Π±Π΅Π· ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠΎΠ² Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²Π° ΠΈΠ»ΠΈ прогрСссирования заболСвания; 2-я Π³Ρ€ΡƒΠΏΠΏΠ° – 20 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (срСдний возраст 67,5 Β± 7,9 Π³ΠΎΠ΄Π°) с Π΄ΠΎΠΊΠ°Π·Π°Π½Π½Ρ‹ΠΌ ΠΏΡ€ΠΈ морфологичСском исслСдовании Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²ΠΎΠΌ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ. Π˜ΠΌΠΌΡƒΠ½ΠΎΠ³ΠΈΡΡ‚ΠΎΡ…ΠΈΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠ΅ исслСдованиС ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ стрСптавидин-Π±ΠΈΠΎΡ‚ΠΈΠ½ΠΎΠ²Ρ‹ΠΌ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ. Π’ΠΎ всСх случаях использовали Π°Π½Ρ‚ΠΈΡ‚Π΅Π»ΠΎ Anti-LC3B antibody ab48394. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ Ρ€Π΅Π°ΠΊΡ†ΠΈΠΈ подсчитывали ΠΏΠΎ систСмС Histochemical score (Hs).Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π”ΠΎ лСчСния Ρƒ всСх ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ зафиксирована умСрСнная цитоплазматичСская экспрСссия (Hs = 111 [111; 115]) Π°Π½Ρ‚ΠΈΡ‚Π΅Π» ΠΊ LC3B Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… Π°Π΄Π΅Π½ΠΎΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, Ρƒ 5 % – слабая цитоплазматичСская экспрСссия Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΌΡ‹ΡˆΠ΅Ρ‡Π½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡ‚ΠΊΠ°Π½Π½ΠΎΠΉ стромы (Hs = 47 [43; 50]), Ρƒ 10 % – слабая ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ рСакция LC3B Π² стСнкС сосудов (Hs = 28 [20; 35]). ПослС лСчСния экспрСссия LC3B Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… Π°Π΄Π΅Π½ΠΎΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ стала ΠΎΡ‚Ρ€ΠΈΡ†Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ, Π² Ρ†ΠΈΡ‚ΠΎΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΌΡ‹ΡˆΠ΅Ρ‡Π½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡ‚ΠΊΠ°Π½Π½ΠΎΠΉ стромы – слабой (Hs = 75 [67,5; 80,0]), Π² эндотСлии сосудистой стСнки – Π΅Ρ‰Π΅ слабСС (Hs = 55 [45,5; 60,0]) (Ρ€ <0,001). Π”ΠΎ лСчСния Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅ Ρƒ 89 % ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² выявлСна умСрСнная экспрСссия LC3B Π² ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ(Hs = 151,5 [137,5; 160,0]), Ρƒ 12 % – слабая экспрСссия Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΌΡ‹ΡˆΠ΅Ρ‡Π½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡ‚ΠΊΠ°Π½Π½ΠΎΠΉ стромы (Hs = 44 [35; 51,5]), Ρƒ 5 % – слабая экспрСссия Π² стСнкС сосудов (Hs = 30 [25; 35]). ПослС лСчСния экспрСссия LC3B Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… Π°Π΄Π΅Π½ΠΎΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ стала Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΠΉ (Hs = 260 [250; 285]), Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΌΡ‹ΡˆΠ΅Ρ‡Π½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡ‚ΠΊΠ°Π½Π½ΠΎΠΉ стромы – ΡƒΠΌΠ΅Ρ€Π΅Π½Π½ΠΎΠΉ (Hs = 118 [100; 130]), Π² сосудистой стСнкС – слабой (Hs = 45 [30; 55]) (Ρ€ <0,001). Зафиксирована значимая ассоциация ΠΌΠ΅ΠΆΠ΄Ρƒ Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²ΠΎΠΌ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΈ гипСрэкспрСссиСй LC3B (r = 0,51; p <0,001).Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ²Π° Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ связано с ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½ΠΈΠ΅ΠΌ экспрСссии Π°ΡƒΡ‚ΠΎΡ„Π°Π³ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° LC3B. ΠŸΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½Π°Ρ экспрСссия LC3B, которая интСрпрСтируСтся ΠΊΠ°ΠΊ ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠΈ Π°ΡƒΡ‚ΠΎΡ„Π°Π³ΠΈΠΈ ΠΈ ΠΊΠΎΡ€Ρ€Π΅Π»ΠΈΡ€ΡƒΠ΅Ρ‚ с риском прогрСссирования заболСвания, ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅Ρ‚ΡΡ ΠΎΠΏΡƒΡ…ΠΎΠ»ΡŒΡŽ ΠΊΠ°ΠΊ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π½ΠΎΠ΅ прСимущСство
    corecore